AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovation
Posted
Jenna Congdon (via MedCity News)
As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational question: Who is responsible for ensuring that these tools remain safe once they enter clinical practice?
The post AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovation appeared first on MedCity News.
